Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fergus Sweeney

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|May 3, 2011
An audience with… Fergus Sweeney. Interview by Asher MullardFergus Sweeney
Clinical Trials (London, England)|February 18, 2018
The evolution of clinical trials: Can we address the challenges of the future?Hans-Georg Eichler, Fergus Sweeney
Future Medicinal Chemistry|March 24, 2011
Clinical trials in developing countries: risk or opportunity?Agnés Saint Raymond, Fergus Sweeney
The Lancet Regional Health. Europe|October 18, 2021
Shaping EU medicines regulation in the post COVID-19 eraMarco Cavaleri, Fergus Sweeney, Rosa Gonzalez-Quevedo, et al.
Clinical Pharmacology and Therapeutics|December 18, 2019
Big Data - How to Realize the PromiseAlison Cave, Nikolai C Brun, Fergus Sweeney, et al.
The Lancet. Infectious Diseases|February 26, 2022
COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in EuropeEdit Szepessy, Peter Arlett, Fergus Sweeney, et al.
Pharmacoepidemiology and Drug Safety|September 21, 2020
Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human UseAniello Santoro, Irina Caplanusi, Fergus Sweeney, et al.
Expert Review of Clinical Pharmacology|August 27, 2013
European Union Clinical Trials Register: on the way to more transparency of clinical trial dataGunter F Egger, Ralf Herold, Ana Rodriguez, et al.
Clinical Pharmacology and Therapeutics|May 15, 2020
Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?Hans-Georg Eichler, Marco Cavaleri, Harald Enzmann, et al.
Clinical Trials (London, England)|April 22, 2016
Enhancing clinical evidence by proactively building quality into clinical trialsAnn Meeker-O'Connell, Coleen Glessner, Mark Behm, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|May 3, 2011
An audience with… Fergus Sweeney. Interview by Asher MullardFergus Sweeney
Clinical Trials (London, England)|February 18, 2018
The evolution of clinical trials: Can we address the challenges of the future?Hans-Georg Eichler, Fergus Sweeney
Future Medicinal Chemistry|March 24, 2011
Clinical trials in developing countries: risk or opportunity?Agnés Saint Raymond, Fergus Sweeney
The Lancet Regional Health. Europe|October 18, 2021
Shaping EU medicines regulation in the post COVID-19 eraMarco Cavaleri, Fergus Sweeney, Rosa Gonzalez-Quevedo, et al.
Clinical Pharmacology and Therapeutics|December 18, 2019
Big Data - How to Realize the PromiseAlison Cave, Nikolai C Brun, Fergus Sweeney, et al.
The Lancet. Infectious Diseases|February 26, 2022
COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in EuropeEdit Szepessy, Peter Arlett, Fergus Sweeney, et al.
Pharmacoepidemiology and Drug Safety|September 21, 2020
Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human UseAniello Santoro, Irina Caplanusi, Fergus Sweeney, et al.
Expert Review of Clinical Pharmacology|August 27, 2013
European Union Clinical Trials Register: on the way to more transparency of clinical trial dataGunter F Egger, Ralf Herold, Ana Rodriguez, et al.
Clinical Pharmacology and Therapeutics|May 15, 2020
Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?Hans-Georg Eichler, Marco Cavaleri, Harald Enzmann, et al.
Clinical Trials (London, England)|April 22, 2016
Enhancing clinical evidence by proactively building quality into clinical trialsAnn Meeker-O'Connell, Coleen Glessner, Mark Behm, et al.
Pageof 2